Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Duruisseaux

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Current Drug Targets|October 21, 2009
The role of pemetrexed in lung adenocarcinoma, mixed subtype with bronchioloalveolar carcinoma featuresMichael Duruisseaux, Jacques Cadranel, Maurice Pérol, et al.
Frontiers in Immunology|April 9, 2020
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?Morgane Denis, Michael Duruisseaux, Marie Brevet, et al.
Frontiers in Oncology|September 20, 2024
Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancerAli Chour, Anne-Claire Toffart, Elodie Berton, et al.
Annales De Pathologie|January 19, 2016
[Pulmonary sarcomatoid carcinoma]Martine Antoine, Thibault Vieira, Vincent Fallet, et al.
Journal of Thoracic Disease|September 8, 2022
Futile lobectomies following video-thoracoscopic exploration for indeterminate pulmonary nodules: a retrospective studyGabrielle Drevet, Yaniss Belaroussi, Michael Duruisseaux, et al.
Cancer Treatment Reviews|August 7, 2024
Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literatureAnne-Laure Désage, Michael Duruisseaux, Claire Lafitte, et al.
Biomarker Research|June 19, 2026
3D bioprinting for cancer modeling and drug screeningAurélie Cadiou, Eva-Laure Peiller Matera, Nicolas Ellinger, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophagesThibault Vieira, Martine Antoine, Cécile Hamard, et al.
Lung Cancer (Amsterdam, Netherlands)|January 28, 2014
The impact of intracytoplasmic mucin in lung adenocarcinoma with pneumonic radiological presentationMichael Duruisseaux, Martine Antoine, Nathalie Rabbe, et al.
Scientific Reports|May 17, 2025
COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitorsAugustin Boudoussier, Iban Larrouture, Pauline Henrot, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Current Drug Targets|October 21, 2009
The role of pemetrexed in lung adenocarcinoma, mixed subtype with bronchioloalveolar carcinoma featuresMichael Duruisseaux, Jacques Cadranel, Maurice Pérol, et al.
Frontiers in Immunology|April 9, 2020
How Can Immune Checkpoint Inhibitors Cause Hyperprogression in Solid Tumors?Morgane Denis, Michael Duruisseaux, Marie Brevet, et al.
Frontiers in Oncology|September 20, 2024
Mechanisms of resistance to KRASG12C inhibitors in KRASG12C-mutated non-small cell lung cancerAli Chour, Anne-Claire Toffart, Elodie Berton, et al.
Annales De Pathologie|January 19, 2016
[Pulmonary sarcomatoid carcinoma]Martine Antoine, Thibault Vieira, Vincent Fallet, et al.
Journal of Thoracic Disease|September 8, 2022
Futile lobectomies following video-thoracoscopic exploration for indeterminate pulmonary nodules: a retrospective studyGabrielle Drevet, Yaniss Belaroussi, Michael Duruisseaux, et al.
Cancer Treatment Reviews|August 7, 2024
Toxicities associated with sequential or combined use of immune checkpoint inhibitors and small targeted therapies in non-small cell lung cancer: A critical review of the literatureAnne-Laure Désage, Michael Duruisseaux, Claire Lafitte, et al.
Biomarker Research|June 19, 2026
3D bioprinting for cancer modeling and drug screeningAurélie Cadiou, Eva-Laure Peiller Matera, Nicolas Ellinger, et al.
Lung Cancer (Amsterdam, Netherlands)|July 10, 2016
Sarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1) and strong immune-cell infiltration by TCD3 cells and macrophagesThibault Vieira, Martine Antoine, Cécile Hamard, et al.
Lung Cancer (Amsterdam, Netherlands)|January 28, 2014
The impact of intracytoplasmic mucin in lung adenocarcinoma with pneumonic radiological presentationMichael Duruisseaux, Martine Antoine, Nathalie Rabbe, et al.
Scientific Reports|May 17, 2025
COPD patients with non-small cell lung cancer respond better to anti-PD-(L)1 immune checkpoint inhibitorsAugustin Boudoussier, Iban Larrouture, Pauline Henrot, et al.
Pageof 4